A patent based on the work from Dr. Rong Li’s team has led to a Phase 1 clinical trial PRTH-101, a Novel DDR1 Inhibitor for the Treatment of Immune-Excluded Solid Tumors.
A patent based on the work from Dr. Rong Li’s team has led to a Phase 1 clinical trial PRTH-101, a Novel DDR1 Inhibitor for the Treatment of Immune-Excluded Solid Tumors.